stockrowBristol Myers Squibb Company
BMY Healthcare Drug Manufacturers General
Bristol Myers Squibb Company’s revenue for fiscal 2025 (year ended December 2025) was $48.2 billion, roughly unchanged from fiscal 2024.
- Revenue
- +6.93%
- EPS
- −2.02%
- Free cash flow
- −36.0%
- Total debt
- −12.5%
Quarter to September 2026, against a year earlier
Follow BMY
Alert me
Bristol Myers Squibb Company (BMY) Return on invested capital
Bristol Myers Squibb Company's return on invested capital over the twelve months to 30 September 2026 was 13.2%, up 2.2 percentage points from fiscal 2025 (11.0%). Over the past ten years it has ranged from −9.49% (fiscal 2024) to 29.3% (fiscal 2018); the current reading is higher than 73% of that period. That is above the Drug Manufacturers General industry median of 6.26% and above the Healthcare sector median of 0.00%.
Return on invested capital, annual
Embed this chart
Annual newest first
| Period | Return on invested capital | Change (points) |
|---|---|---|
| FY2025 | 11.0% | 20.50 |
| FY2024 | −9.49% | (18.75) |
| FY2023 | 9.26% | 1.38 |
| FY2022 | 7.88% | (0.08) |
| FY2021 | 7.96% | 13.86 |
| FY2020 | −5.90% | (9.64) |
| FY2019 | 3.74% | (25.59) |
| FY2018 | 29.3% | 4.66 |
| FY2017 | 24.7% | 2.54 |
| FY2016 | 22.1% | 14.42 |
Against its own ten years
Return on invested capital against peers
| Company | Return on invested capital |
|---|---|
| NVO Novo Nordisk A/S compare | 28.7% |
| AMGN Amgen Inc. compare | 14.3% |
| BMY Bristol Myers Squibb Company | 13.2% |
| AZN AstraZeneca PLC compare | 12.3% |
| NVS Novartis AG compare | 12.1% |
| GSK GSK PLC Sponsored ADR compare | 9.61% |
| SNY Sanofi compare | 7.05% |
| PFE Pfizer Inc. compare | 6.19% |
| GILD Gilead Sciences, Inc. compare | −4.51% |
| Drug Manufacturers General industry median | 6.26% |
| Healthcare sector median | 0.00% |
| Market median | 0.00% |
What Return on invested capital is
Return on Invested Capital shows how much after-tax operating profit a company earns on the money its lenders and shareholders have put in.
TTM: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) (latest quarter) + Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter) − Cash & Short Term Investments (latest quarter)); Annual: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) + Long Term Debt (Total) + Current Part of Debt − Cash & Short Term Investments)
More on BMY
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement